Blocking HIV-1 entry by a gp120 surface binding inhibitor
- 1 May 2012
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (9), 3358-3361
- https://doi.org/10.1016/j.bmcl.2012.02.079
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (GM35208, AI-38204, AI-065310)
This publication has 26 references indexed in Scilit:
- Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffoldBioorganic & Medicinal Chemistry Letters, 2010
- Resistance to novel drug classesCurrent Opinion in HIV and AIDS, 2009
- Synthetic Mimetics of the CD4 Binding Site of HIV‐1 gp120 for the Design of ImmunogensAngewandte Chemie, 2007
- Risk factors and prevalence of HIV infection in people seeking health care in an STI clinic in BrazilAIDS Care, 2007
- Strategies for Targeting Protein–Protein Interactions With Synthetic AgentsAngewandte Chemie, 2005
- Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptorsOncogene, 2005
- Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its ReceptorCancer Research, 2004
- Single‐Dose Safety, Pharmacology, and Antiviral Activity of the Human Immunodeficiency Virus (HIV) Type 1 Entry Inhibitor PRO 542 in HIV‐Infected AdultsThe Journal of Infectious Diseases, 2000
- Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 IsolatesAIDS Research and Human Retroviruses, 1995
- HIV infection is blocked in vitro by recombinant soluble CD4Nature, 1988